跳至主要内容
临床试验/NL-OMON32710
NL-OMON32710尚未招募不适用

Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib) - Study to immuneresponse in patients treated with a tki

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 75 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks, or patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
  • - Patients who are indicated for influenza vaccination and and have been summoned for this vaccination by their GP
  • - age >=18 years
  • - signed Informed Consent Form

排除标准

  • - patients with an identified immunodeficiency disorder
  • - patients that have been treated with corticosteroids in the past 2 weeks or who are still using these (except for a short period <10 days)
  • - patients that are treated with immunotherapy in the last year (ex. interferon-alpha of IL-2) or who have received another form of targeted therapy (ex. bevacizumab).
  • - patients with symptoms of influenza at the time of vaccination
  • - patient with an allergy for

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验

Study to the humoral and cellular immuneresponse... | 临床试验